Ann: Middle East is next market for PromarkerD immunoassay test, page-33

Hi Katy,

Very happy to see that you are still around & excellent post, thank you. I agree.

@jojosydney, we have so often had upside and downside on no news & can change in a day. I just roll my eyes now LOL.

We know that we are expecting Janssen news soon as Katy pointed out earlier. This is what we are waiting on for the FDA Application & the long awaited CDx. It does not mean that deals won’t happen in the USA prior to this. PromarkerD can be run in CLIA approved labs, now. With EU CE Mark for some time now, that may happen there sooner. ISO13845 application is in for IVD test, we have it for Mass Spectrometry. Internationally recognised codes. Richard knows what he is doing.

There has been progress over the last month with 2 deals announced, Italy & Israel. Italy has completed regulatory approval within the one month time frame announced, so this is a positive reflection on the Consultancy/distribution company they have engaged (see @Eqz post late last week), especially considering the country is in lockdown with COVID-19.

It is entirely possible the Ministry of Health in Israel may fast track PromarkerD in the current situation with COVID-19 & the burden that DKD/CKD patients if infected could create for their health system in a Pandemic.

If you look at the UK & USA, it was 1/4-1/3 I think from memory of all patient deaths that had diabetes (old data, but articles posted prior).

It’s now well known that diabetes is a massive risk factor for ICU admission & mortality, even inducing DKD/CKD in patients with no prior kidney involvement. For a nation with 1 in 8 adults with diabetes, the GOVT have already mandated reporting on ESRD & dialysis, this could not only be a good thing for physicians & their patients, but also have a role in public health planning & risk mitigation.

MCP-1 and there are some others as well, are now known biomarkers for patients at risk of severe COVID-19. People with diabetes have elevated MCP-1. (See research).

I think people started looking past the research PromarkerD were doing on COVID-19 testing as well with a dry spell of cases.

1. A rapid diagnostic saliva test.

2. A blood test to determine severity of disease.

What is happening again now in South Australia & the majority of the world, demonstrates that research is still very viable in testing & how quickly things can escalate. I actually wonder if it wasn’t for the 80yo going to hospital in that cluster, would it have been ever picked up, or so quickly?

Now a hospital ED, Nursing Home, Gaol, 2 schools, a preschool, multiple shopping precincts, public transport routes.. All from a Quarantine Hotel & a couple of people.

Rapid tests can be quite inaccurate & we now have serology available for antibodies for NSW Health. It would be really interesting to see how many people actually have been exposed & have antibodies...I’ll hold my arm out for that for research for a blood test. I think it will be really interesting, especially with the whole sewerage testing thing. In SW Sydney so one of the “problem areas” since this began. I believe it’s still circulating & this time of year, allergies can mimic cold symptoms & vice versa, particularly in children who can be otherwise asymptomatic with COVID-19, or present with mild cold like symptoms. Easily missed, or basically how do you know unless a fever?

Just have to look past the noise on PIQ.

GLTAH